Suboptimal Ciprofloxacin Dosing as a Potential Cause of Decreased Pseudomonas aeruginosa Susceptibility in Children with Cystic Fibrosis

Study Objective. To assess the probability of achieving ciprofloxacin pharmacodynamic targets with currently recommended dosages in order to investigate the risk of ciprofloxacin underexposure in children with cystic fibrosis.

[1]  J. Treluyer,et al.  Drug Disposition in Cystic Fibrosis , 1998, Clinical pharmacokinetics.

[2]  F. Sörgel,et al.  Pharmacokinetic Optimisation of the Treatment of Bacterial Central Nervous System Infections , 1998, Clinical pharmacokinetics.

[3]  M. Hodson,et al.  Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis , 1986, Antimicrobial Agents and Chemotherapy.

[4]  H. Coutinho,et al.  Pulmonary bacterial pathogens in cystic fibrosis patients and antibiotic therapy: a tool for the health workers , 2008, International archives of medicine.

[5]  A. Prince,et al.  Opportunistic infections in lung disease: Pseudomonas infections in cystic fibrosis. , 2007, Current opinion in pharmacology.

[6]  A. Oliver,et al.  Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  Y. Aigrain,et al.  Population Pharmacokinetics of Ciprofloxacin in Pediatric and Adolescent Patients with Acute Infections , 2003, Antimicrobial Agents and Chemotherapy.

[8]  B. Strandvik,et al.  Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients , 1992, Antimicrobial Agents and Chemotherapy.

[9]  Jerome J. Schentag,et al.  Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates Part 2: Human Trials , 2003, The Annals of pharmacotherapy.

[10]  A. Rodloff,et al.  Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times. , 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[11]  R. Echols,et al.  Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group. , 1997, The Pediatric infectious disease journal.

[12]  E. Gulbins,et al.  Cystic fibrosis and innate immunity: how chloride channel mutations provoke lung disease , 2009, Cellular microbiology.

[13]  J J Schentag,et al.  Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients , 1993, Antimicrobial Agents and Chemotherapy.

[14]  Jerome J. Schentag,et al.  Pharmacodynamic Evaluation of Factors Associated with the Development of Bacterial Resistance in Acutely Ill Patients during Therapy , 1998, Antimicrobial Agents and Chemotherapy.

[15]  P. de Micco,et al.  Penetration of ciprofloxacin into bronchial secretions from mechanically ventilated patients with nosocomial bronchopneumonia , 1994, Antimicrobial Agents and Chemotherapy.

[16]  M. V. Miles,et al.  Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. , 1997, The Pediatric infectious disease journal.

[17]  M. Gastonguay,et al.  Population Pharmacokinetics of Ciprofloxacin in Pediatric Patients , 2003, Journal of clinical pharmacology.

[18]  Jerome J. Schentag,et al.  Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates , 2003, The Annals of pharmacotherapy.

[19]  P. Tulkens,et al.  Quinolones in 2005: an update. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[20]  G. Kaatz,et al.  Activities of Newer Fluoroquinolones against Ciprofloxacin-Resistant Streptococcus pneumoniae , 2001, Antimicrobial Agents and Chemotherapy.

[21]  M. Salam,et al.  Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission , 1995, The Pediatric infectious disease journal.

[22]  D. Touw.  Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis. , 1998, Pharmacy World and Science.

[23]  A. Smith,et al.  Pharmacokinetics of ciprofloxacin in cystic fibrosis , 1987, Antimicrobial Agents and Chemotherapy.

[24]  Jerome J. Schentag,et al.  Pharmacodynamic Modeling of Risk Factors for Ciprofloxacin Resistance in Pseudomonas aeruginosa , 2000, Infection Control & Hospital Epidemiology.

[25]  U. Schaad,et al.  Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients , 1996, Antimicrobial agents and chemotherapy.